Compositions and methods that inhibit il-23 signaling
US-2024425579-A1 · Dec 26, 2024 · US
Methods of treating diseases
US2016304602A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016304602-A1 |
| Application number | US-201615097722-A |
| Country | US |
| Kind code | A1 |
| Filing date | Apr 13, 2016 |
| Priority date | Apr 14, 2015 |
| Publication date | Oct 20, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention generally relates to methods for the treatment of respiratory diseases, such as asthma, utilizing anti-IL-23A antibodies.
First claim
Opening claim text (preview).
1 . A method for treating severe persistent asthma comprising administering to a patient an anti-IL-23A antibody. 2 . The method according to claim 1 , wherein said patient is not responsive to corticosteroids. 3 . The method according to claim 1 , wherein said anti-IL-23A antibody is Antibody A, Antibody B, Antibody C or Antibody D. 4 . The method according to claim 1 , wherein said anti-IL-23A antibody is administered to said patient by subcutaneous administration. 5 . The method according to claim 1 , wherein said asthma is neutrophilic asthma, eosinophilic asthma, mixed neutrophilic and eosinophilic asthma or paucigranulocytic asthma. 6 . The method according to claim 1 , wherein the anti-IL-23A antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:18 and a heavy chain comprising the amino acid sequence of SEQ ID NO:19. 7 . The method according to claim 1 , wherein the anti-IL-23A antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:18 and a heavy chain comprising the amino acid sequence of SEQ ID NO:20. 8 . The method according to claim 1 , wherein the anti-IL-23A antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:21 and a heavy chain comprising the amino acid sequence of SEQ ID NO:19. 9 . The method according to claim 1 , wherein the anti-IL-23A antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 21 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 20.
Assignees
Inventors
Classifications
Drugs for disorders of the respiratory system · CPC title
Antiasthmatics · CPC title
comprising antibodies · CPC title
Igs containing Ig-regions, -domains or -residues form different species · CPC title
- C07K16/244Primary
Interleukins [IL] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016304602A1 cover?
- This invention generally relates to methods for the treatment of respiratory diseases, such as asthma, utilizing anti-IL-23A antibodies.
- Who is the assignee on this patent?
- Boehringer Ingelheim Int
- What technology area does this patent fall under?
- Primary CPC classification C07K16/244. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Oct 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).